Lupin, Dr. Reddy’s to expand operations overseas - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Mar 10, 2000 - Lupin, Dr. Reddy’s to expand operations overseas

Lupin, Dr. Reddy’s to expand operations overseas

Mar 10, 2000

Lupin Laboratories (Lupin) and Dr. Reddy’s Laboratories (DRL) both have plans for aggressive forays into the global arena. While the former is planning to target the cefotexamine market in the USA, the later is stepping on the gas by setting up joint ventures in China and Brazil.DRL is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has grown from being a bulk drug company to a respected formulation based company. It has products such as omeprazole (gastro–intestinal), ciprolet (anti–infective) Nise (pain and fever), Enam (cardiovascular) etc.

Lupin is a world leader in anti–TB drugs. It holds 70–75% of the world market of a major anti–TB drug ethambutol. Nearly 48% of the company’s turnover is contributed by anti–TB drugs.

So far Hoechst Marion Roussel (HMR) has a dominant market share of around $ 120 m in the cefotexamine market in the US and holds the process patent. Normally the originator (i.e. the first company) allows a second entrant a 20% market share without getting into a price war. If this were to happen in the current case, Lupin can target a market of $ 24 m (Rs 1056 m) without risking retaliation from HMR.

This would help the company to diversify its product portfolio and also provide it with cash for venturing into newer and more lucrative products such as those relating to the cardiovascular where the company has a miniscule presence.

DRL on the other hand already has a well–established export business in the CIS countries. However, the Russian crisis last year caused a lot of bad debts for the company. The company wrote off around Rs 250 m over a period of two year’s. The Chinese market is a relatively closed market, hence the need for a joint venture with a Chinese company.

Equitymaster requests your view! Post a comment on "Lupin, Dr. Reddy’s to expand operations overseas". Click here!


More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Nov 26, 2021 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks